Rimonabant for sale, an investigational drug that is a cannabinoid-1 receptor blocker, promoted modest but sustained decreases in weight and waist circumference when combined with a low-calorie diet, reported Dr. F. Xavier Pi-Sunyer of the Obesity Research Center at St. Luke’s-Roosevelt Hospital, New York, and associates.

The drug also improved cardiometabolic risk factors in the multicenter Rimonabant for sale in Obesity-North America (RIO-NA) trial, the researchers said.

Central cannabinoid-1 receptor activation stimulates appetite. Rimonabant reduces overactivation of these receptors …

We may at last have the long-awaited anti-fat wonder drug. Sanofi-Aventis’s Acomplia (rimonabant) helps people to lose weight, stop smoking and, unexpectedly, increase their good cholesterol levels.

Despite a history of failures in the field, investors expect the drug to shine simply because of the huge market for a safe, effective drug to tackle obesity. The world’s obese population has ballooned to about 400m, and the US …

To people who have struggled for a lifetime to lose weight, the new drug called rimonabant sounds like a dream come true.

It will make a person uninterested in fattening foods, they have heard from news reports and word of mouth. Weight will just melt away, and fat accumulating around the waist and abdomen will be the first to go. And by the way, those who take it will end up with higher levels of HDL, the good cholesterol. If they smoke, they will find it easier to quit. If they are heavy drinkers, they will no longer crave alcohol.

“Holy cow, does it also grow hair?” asked Dr. Catherine D. DeAngelis, editor of The Journal of the American Medical Association.

At obesity treatment centers, nearly every patient asks for rimonabant sale– or Acomplia, as it will be called if its maker, Sanofi- Aventis, gets approval to market it in the United States.

But many medical researchers say not so fast. While Rimonabant for sale may be intriguing, these experts say, the mythology in the making is hardly justified by what is known so far.

There are no published studies from clinical trials to justify any of the claims for what some patients are already calling a miracle drug. The data that the company has presented indicate that rimonabant is about as effective for weight loss in obese people as two other drugs already on the market.

Rimonabant has not been approved for sale in the United States or anywhere else. Sanofi-Aventis has not yet submitted its application for marketing to the Food and Drug Administration. The company says it plans to apply early next year.